CytoDyn (OTCMKTS:CYDY) Posts Quarterly Earnings Results

CytoDyn (OTCMKTS:CYDY) released its earnings results on Friday. The biotechnology company reported ($0.02) EPS for the quarter, reports.

CytoDyn Stock Performance

CytoDyn stock traded up $0.00 during midday trading on Friday, hitting $0.28. 310,311 shares of the company’s stock were exchanged, compared to its average volume of 1,262,530. The company has a market cap of $353.17 million, a P/E ratio of -27.80 and a beta of 1.12. The stock has a 50-day moving average price of $0.29 and a two-hundred day moving average price of $0.29. CytoDyn has a 52-week low of $0.13 and a 52-week high of $0.49.

About CytoDyn

CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.

In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.